1-3 of 3
MB van 't Veer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 290.
https://doi.org/10.1182/blood.V118.21.290.290
Published: 2011
Journal Articles

Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation

EJ Gerritsen, MJ Van Tol, MB Van 't Veer, JM Wels, IM Khouw, CR Touw, CM Jol-Van Der Zijde, J Hermans, HC Rumke, J Radl
Journal: Blood
Blood (1994) 84 (12): 4374–4382.
https://doi.org/10.1182/blood.V84.12.4374.bloodjournal84124374
Published: 1994
Journal Articles

Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen

PJ van Genderen, T Vink, JJ Michiels, MB van 't Veer, JJ Sixma, HH van Vliet
Journal: Blood
Blood (1994) 84 (10): 3378–3384.
https://doi.org/10.1182/blood.V84.10.3378.3378
Published: 1994